BCAX Bicara Therapeutics Inc.
$24.28
Bicara Therapeutics Inc. (BCAX) is expected to report earnings on November 10, 2026, before the market open. The consensus earnings estimate is a loss of $0.85 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +6.5% since its last earnings release on August 11, 2026.
Bicara Therapeutics Inc. Missed Consensus Estimates
Tuesday, August 11, 2026 · 7:30 AM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 10
Tuesday · 7:30 AM ET
Earnings Whisper
-
vs ($0.85)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP
$23.99
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Bicara Therapeutics Inc.
Bicara Therapeutics is a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors.
Sector
Healthcare
Industry
Biotechnology